CB-839 Chemical Properties

Melting point:

186- 189° C

Density 

1.430±0.06 g/cm3(Predicted)

storage temp. 

+2C to +8C

solubility 

Soluble in DMSO.

form 

Yellow solid

pka

8.25±0.50(Predicted)

color 

Pale yellow

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.

InChIKey

PRAAPINBUWJLGA-UHFFFAOYSA-N

SMILES

C1(CC(NC2=NN=C(CCCCC3=NN=C(NC(CC4=CC=CC(OC(F)(F)F)=C4)=O)C=C3)S2)=O)=NC=CC=C1

CB-839 Usage And Synthesis

Description

CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.

In vitro

CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.

In vivo

In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.

Description

CB-839 (14393999-58-2)?is a potent (IC50?= 24 nM), selective and orally bioavailable inhibitor of glutaminase (KGA and GAC).1?CB-839 displayed an antiproliferative effect in the triple-negative breast cancer cell line, HCC-1806, but no activity in the estrogen receptor-positive cell line T47D.? CB-839 was able to cause proliferation arrest and apoptosis in acute myeloid leukemia cells without causing cytotoxicity against normal human CD34(+) progenitors.2? Aspartate-glutamate carrier 1 (AGC1) inhibition can synergize with CB-839 to limit tumor growth.3

Uses

CB-839 performs an antileukemic activity. It Inhibits GLS1 genes and reduces oxidative phosphorylation leading to leukamic cell proliferation arrest and apoptosis.

Synthesis

In a 250 mL three-necked round-bottomed flask, N-[6-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-3-pyridazinyl]-3-(trifluoromethoxy)benzeneacetamide (5.5 g, 12.3 mmol, 1.0 eq.) was dissolved in N,N-dimethylacetamide (44 mL, 8.0 v/v). Pyridine-2-acetic acid (2.56 g, 14.8 mmol, 1.2 equiv) was added. Propylphosphonic anhydride (50% ethyl acetate solution, 11.0 g, 17.3 mmol, 1.41 eq.) was added dropwise through the addition funnel at a rate of 5 mL/min. During the dropwise addition, the internal temperature of the reaction solution was increased from 20.1°C to 26.1°C. The reaction was typically completed after 4 h (monitored by LC/MS). Upon completion of the reaction, the reaction solution was cooled to 0°C and diluted with methyl ethyl ketone (50 mL). Water (50 mL) was added and the pH was adjusted to 6 with 2.5 N aqueous sodium hydroxide (28 mL). a yellow precipitate was collected by diafiltration and washed with isopropanol and water (1:1, 50 mL). The solid was transferred to a 100 mL round bottom flask and slurried in isopropanol and water (9:1, 50 mL). The slurry was heated to 65.1 °C and maintained for 8 h, followed by cooling to room temperature over 16 h. The slurry was then removed from the flask. An off-white precipitate was collected by filtration and washed with isopropanol (10 mL). The product was dried under high vacuum to constant weight to afford 2-(pyridin-2-yl)-N-(5-(5-(4-(6-(2-(3-(trifluoromethoxy)phenyl)acetamido)pyridazin-3-yl)butyl)-1,3,4-thiadiazol-2-yl)acetamide (CB-839) in a yield of 5.27 g (76%).1H NMR (300 MHz, DMSO-d6) δ 12.67 (s, 1H), 11.32 (s, 1H), 8.53-8.49 (m, 1H), 8.22-8.19 (d, J=9.12Hz, 1H), 7.78-7.76 (t, 1H), 7.58-7.26 (m, 7H), 4.01 (s, 2H), 3.87 (s, 2H), 3.01 (bs, 2H) , 2.90 (bs, 2H), 1.73 (bs, 4H).The XRD pattern (form B) of the free base of CB-839 is shown in Fig. 2, with characteristic peaks located at 2θ values of 3.64; 7.32; 7.92; 8.53; 9.30; 9.38; 11.02; 11.98; 14.70; 15.54; 15.87; 16.50 16.59; 18.06; 18.39; 19.10; 20.06; 20.12; 20.61; 21.37; 21.89; 22.41; 22.74; 23.72; 24.10; 24.65; 25.14; 25.78; 26.49; 27.32; 27.55; 28.26; 29.88. 31.20; 31.80; 31.52; 32.80; 34.30; 35.20; 36.41; 38.53; 40.08; 40.94; and 43.86.

in vivo

storage

Store at -20°C

References

[1] MATT I GROSS. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.[J]. Molecular Cancer Therapeutics, 2014, 13 4: 890-901. DOI:10.1158/1535-7163.mct-13-0870
[2] NATHALIE JACQUE. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.[J]. Blood, 2015, 126 11: 1346-1356. DOI:10.1182/blood-2015-01-621870
[3] H FURKAN ALKAN. Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.[J]. Cell metabolism, 2018, 28 5: 706-720.e6. DOI:10.1016/j.cmet.2018.07.021

CB-839(1439399-58-2)Related Product Information

• Cantharidin
• Geldanamycin
• AG 490
• Vorinostat
• Selumetinib
• JNJ7777120
• GDC-0152
• AVP-AEW541
• Nutlin-3
• Forskolin